For research use only. Not for therapeutic Use.
BMH-21 is a first-in-class DNA intercalator which inhibits RNA polymerase I (Pol I) transcription. BMH-21 possesses anticancer activity[1][2].
BMH-21 binds ribosomal DNA and inhibits Pol I transcription[1].?
BMH-21 inhibits RNA polymerase I independent of DNA damage response[1].?
BMH-21 intercalates into double strand (ds) DNA and has binding preference towards GC-rich DNA sequences[1].?
BMH-21 (1 μM; 3 hours) acts in a DNA damage independent manner to activate nucleolar stress and RPA194 degradation[1].
BMH-21 (50 mg/kg; i.p.; daily; for 6 days) inhibits HCT116 colon cancer tumor growth in vivo[2].
| Catalog Number | I005364 |
| CAS Number | 896705-16-1 |
| Synonyms | N-[2-(dimethylamino)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide |
| Molecular Formula | C21H20N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H20N4O2/c1-24(2)11-9-22-20(26)16-8-5-10-25-19(16)23-18-13-15-7-4-3-6-14(15)12-17(18)21(25)27/h3-8,10,12-13H,9,11H2,1-2H3,(H,22,26) |
| InChIKey | BXYDVWIAGDJBEC-UHFFFAOYSA-N |
| SMILES | CN(C)CCNC(=O)C1=CC=CN2C1=NC3=CC4=CC=CC=C4C=C3C2=O |
| Reference | [1]. Colis L, et al. DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response. Oncotarget. 2014 Jun 30;5(12):4361-9. [2]. Karita Peltonen, et al. A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity. Cancer Cell. 2014 Jan 13; 25(1): 77–90. |
